0211 Cyteir series C

BioCentury & Getty Images


Public listing, Phase II cancer readouts in Cyteir’s sights as it banks $80M crossover round

Feb 12, 2021 | 12:30 AM GMT

With early efficacy signals emerging from a dose-finding study, Cyteir will use its new $80 million series C crossover round to gain Phase II data in multiple cancers for its DNA damage repair (DDR) molecule targeting RAD51,

Read the full 654 word article

How to gain access

Continue reading with a
two-week free trial.